14
SEP
2020

IMEOF and its active presence in web or online conferences (webinar)

Posted By :
Comments : 0
  • In recent weeks IMEOF (through one of its members, AEPROMO) has been invited to give conferences through the webinar system, organized in different parts of the world.

 

  • IMEOF (through one of its members, AEPROMO), has accepted the invitations, developing topics related to the use of ozonized saline solution, a route of application of ozone therapy, as a complementary therapy to face COVID-19.

“Ozone therapy for COVID-19”. Webinar organized by the Russian Association of Ozone Therapy. August 20, 2020.

Speaker: Dra. Adriana Schwartz, president of AEPROMO, IMEOF, and scientific secretary of ISCO3.

“Ozone therapy as a complementary treatment in patients with COVID-19, to reduce sequelae and disabilities.” Webinar organized by the Society of Physical Medicine and Rehabilitation, Peru. August 22 and 23, 2020.

Speaker: Dr. Adriana Schwartz, president of AEPROMO, IMEOF and scientific secretary of ISCO3. She gave two presentations; She also participated in two panel discussions and in the round table.

Speaker: Roberto Quintero, Legal Advisor of AEPROMO. IMEOF and ISCO3. Presentation: “Ozone Therapy, Legality, and Covid-19”.

“Scientific advances in ozone therapy”. Webinar organized by the Brazilian Institute of Ozone and its Applications. September 6, 2020.

Speaker: Dr. Gregorio Martínez. Member of AEPROMO and president of ISCO3.

Upcoming participation

International Congress of Advanced Therapies. México. October 10-11, 2020.

Keynote lecture by Dr. Adriana Schwartz, president of AEPROMO and IMEOF, scientific secretary of ISCO3.

Click here to watch: https://m.facebook.com/story.php?story_fbid=1865716393571092&id=100003982471568

About the Author
Clara Barrachina: Diseñadora gráfico y web. Diseño de portadas, maquetación de publicaciones. Marketing en Redes sociales. Fotografía y tratamiento de imagen. Renovación de imagen corporativa. Portfolio: Behânce. E-mail: cbarrachinafct@gmail.com.

Leave a Reply